TYPE 2 Diabetes
Patients’ suffering from type 2 diabetes mellitus requires metformin plus something which will help to reduce the cardiovascular risk factors are some of the common aims of the drug therapy. However, the progressive impairment of both the secretion and action of insulin in the condition mean that high blood glucose concentrations usually worsen over time, so necessitating escalation of hypoglycaemic therapy. Three drugs in two new classes that act on the hormonal regulation of insulin secretion have been launched recently. They are:
(1) exenatide (Byetta – Eli Lilly)
(2) sitagliptin (Januvia – MSD).
(3) vildagliptin (Galvus – Novartis).
Comments
Post a Comment